Document:

Exhibit 10.19

AMENDMENT No. 3 to LICENSE AGREEMENT

Amendment No. 3 made and effective as of March 23, 2011 to the License Agreement
dated June 12, 2007 entered into by and between IASO Pharma Inc. (formerly Pacific Beach Biosciences, Inc.), a Delaware corporation having a place of business
at 12707 High Bluff Drive, Suite 200, San Diego, CA 92130 (“Company”) and Dong Wha Pharm. Co. Ltd., a Korean corporation having a place of
business at 5 Soonwha-dong, Joong-ku, Seoul 100-130, Korea (“Licensor”).

WITNESSETH:

WHEREAS, Company and Licensor are party to a License Agreement dated as of June
12th 2007, as amended by Amendment No. 1 thereto dated as of April 22, 2008 and Amendment No. 2 thereto dated as of November 4, 2010 (the “License
Agreement”), pursuant to which Company is developing DW-224a;

WHEREAS, the parties now desire to further amend the License Agreement in
certain respects on the terms and conditions set forth below.

NOW THEREFORE, in consideration of the foregoing premises and the mutual
covenants set forth below, the parties amend the License Agreement and otherwise agree as follows:

1.

Unless otherwise set forth in this Amendment No. 3, each
capitalized term and abbreviation has the meaning set forth in the License Agreement.

2.

Amendments

A.
Section 4.1.3 of the License Agreement is hereby amended to replace references to “February 28, 2011” with
“March 28, 2011.” [Insert date that is 5 days following the execution date of Amendment No. 3
]

B.
Section 7.4.6 of the License Agreement is hereby amended to replace references to “February 28, 2011” with
“June 30, 2011.”

C.
Section 7.4 of the License Agreement is hereby amended to add the following as a new subsection 7.4.7:

7.4.7   In addition to the Financing Milestone, (1)
and in order to provide interim financing for Company pending the achievement of the Financing Milestone, Company shall obtain by no later than April 6, 2011 [
Insert date that is 14 days following execution date of Amendment No. 3] a financing commitment in writing, pursuant to an agreement

or other enforceable
instrument, from Paramount BioSciences, LLC or one or more other Affiliates of Lindsay A. Rosenwald, of at least US$3,000,000 to be drawn by Company when and as
needed to finance Company’s operations and the PB-101 Phase II CAP Study during the period prior to the achievement of the Financing Milestone (the
“Interim Financing Commitment”) and (2) diligently execute such Study without interruption or delay from March 10, 2011 until completion of the
Financing Milestone. Notwithstanding anything to the contrary contained herein, if Company fails to obtain the Interim Financing Commitment by April 6,
2011 or if the Company interrupts or delays the conduct of the foregoing study prior to achievement of the Financing Milestone, such failure shall be deemed to
be a material breach of this Agreement which Company shall have no right to cure and Licensor shall have the right to terminate this Agreement anytime within
ninety (90) days following April 6, 2011, which termination shall be effective immediately upon delivery of written notice. For further clarification,
time is of the essence with respect to the deadline set forth in this Section 7.4.7 and the obligations of Company and the right of Licensor to terminate
provided above shall apply in all events, even if the failure is due to reason(s) beyond the reasonable control of Company.

3.

Representations and Warranties.

(a)

Each party hereby represents and warrants to the other party
as follows:

i)

This Amendment has been duly executed and delivered on behalf
of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms.

ii)

All necessary consents, approvals and authorizations of all
governmental authorities and other entities required to be obtained by such party in connection with this Amendment have been obtained.

(b)

Licensor hereby represents and warrants to Company as
follows:

i)

The License Agreement is in full force and effect in
accordance with its terms. After giving effect to this Amendment, to Licensor’s knowledge, there exist no breaches, defaults or events which would
(with the giving of notice, the passage of time or both) give rise to a breach, default or other right to terminate or modify the License Agreement.

4.

Except as expressly modified by this Amendment No. 3, all of
the terms and conditions of the License Agreement shall continue in effect.

2

IN WITNESS WHEREOF, Company and Licensor, intending to
be bound, have executed this Amendment No. 3 by their duly authorized representatives, and this Amendment No. 3 shall be part of the License Agreement between
the parties as of the date first written above. This Amendment may be executed in counterparts, each of which shall be deemed to be an original and
together shall be deemed to be one and the same agreement.

			
	IASO Pharma Inc.

	 

	By:

	/s/
Matthew A. Wikler

	 
	 

	Name:

	Matthew A. Wikler

	 
	 

	Title:

	President & CEO

			
	Dong Wha Pharm. Co. Ltd.,

	 

	By:

	/s/ Chang Soo Cho

	 
	 

	Name:

	Chang Soo Cho

	 
	 

	Title:

	President & CEO

In addition to the guaranty provided by the undersigned in the License
Agreement, the undersigned hereby unconditionally guarantees to Licensor for the benefit of Company the full and prompt payment of the amount set forth in
Section 4.1.3 of the License Agreement as amended by this Amendment No. 3.

			
	Paramount Biosciences LLC

	 

	By:

	/s/ Lindsay A.
Rosenwald

	 
	 

	Name:

	Lindsay A. Rosenwald

	 
	 

	Title:

	Sole Member

3Exhibit 10.20

EXECUTION VERSION

BACKSTOP COMMITMENT
AGREEMENT

THIS BACKSTOP COMMITMENT AGREEMENT (this “Agreement”), dated as of April 6, 2011, is by and among IASO Pharma Inc., a Delaware corporation (the “Company”), and Manchester
Securities Corp., a New York corporation (“Manchester”), and Lindsay A. Rosenwald, M.D. (“Rosenwald”).  Each of
Manchester and Rosenwald is referred to herein as a “Backstop Investor”).

RECITALS 

WHEREAS, in connection with the Recapitalization
(as defined below), on the terms and subject to the conditions of the Subscription Agreements (as defined below), the Company proposes to offer to each holder
of the Company’s Existing Convertible Notes (as defined below) (each, a “Holder”) the opportunity to subscribe for such Holder’s pro
rata share of the Rights Offering Notes (as defined below) (the “Rights Offering”); 

WHEREAS, subject to the terms and conditions of
this Agreement, each Backstop Investor will subscribe for the full amount of Rights Offering Notes set forth next to such Backstop Investor’s name on
Exhibit A attached hereto;

WHEREAS, the total aggregate principal amount of
Rights Offering Notes being issued by the Company in connection with the Recapitalization is $3,000,000;

WHEREAS, in order to facilitate the
Recapitalization, pursuant to this Agreement, and subject to the terms, conditions and limitations set forth herein and in consideration of the issuance of the
Backstop Warrants (as defined herein), the Company is willing to sell, and each Backstop Investor is willing to purchase (in addition to the amount set forth on
Exhibit A attached hereto), on a several but not joint basis, an aggregate principal amount of Rights Offering Notes equal to 50% of the difference
between (i) $3,000,000 and (ii) the aggregate principal amount of Rights Offering Notes subscribed for by the Holders (including the Backstop Investors and the
Rosenwald Entities) pursuant to the Subscription Agreements (the maximum principal amount of Rights Offering Notes that each Backstop Investor is willing to
purchase (not including the amount set forth on Exhibit A), the “Individual Backstop Cap”); and 

WHEREAS, the Company and each Backstop Investor
is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act (as
defined below), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission under the
Securities Act.

NOW, THEREFORE, in consideration of the
foregoing premises and of the mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows: 

Section 1.

DEFINITIONS.
 

As used in this Agreement, the following terms
shall have the following meanings:  

“Action” means any action, suit,
proceeding, claim or litigation.

“Affiliate” means, with respect
to any specified Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with, such specified Person.  

“Agreement” has the meaning
assigned to it in the preamble hereto.  

“Amendment Agreements” means
those certain Amendment Agreements, each dated as of March 30, 2011, between the Company and the holders of the Existing Convertible Notes.

“Backstop Commitment Amount”
means $3,000,000.

“Backstop Investor” has the
meaning assigned to it in the preamble hereto.  

“Backstop Notes” has the
meaning assigned to it in Section 2.2(a).

“Backstop Warrant” has the
meaning assigned to it in Section 2.3.

“Business Day” means any day
that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed in New York, New York.  

“Closing” has the meaning
assigned to it in Section 2.2(b).  

“Closing Date” has the meaning
assigned to it in Section 2.2(b).

“Common Stock” means the
Company’s common stock, $0.001 par value per share.

“Company” has the meaning
assigned to it in the preamble hereto.  

“Contract” means any contract,
arrangement, note, mortgage, lease, sublease, bond, commitment, purchase order, sales order, franchise, guarantee, indemnity, indenture, instrument, lease,
license or other agreement, understanding, instrument or obligation, whether written or oral, all amendments, supplements and modifications of or for any of the
foregoing and all rights and interests arising thereunder or in connection therewith.  

“control” (including the terms
“controlled by” and “under common control with”), with respect to the relationship between or among two or more Persons, means
the possession, directly or indirectly or as trustee, personal representative or executor, of the power to direct or cause the direction of the affairs,
policies or management of a Person, whether through the ownership of voting securities, as trustee, personal representative or executor, by Contract, credit
arrangement or otherwise.  

“Effective Date” means the
closing date for the purchase and sale of the Rights Offering Notes pursuant to the terms of the Subscription Agreements. 

2

“Effective
Date Notice” has the meaning assigned to it in Section 2.1(c).

“Encumbrance” means any
security interest, pledge, mortgage, lien, claim, option, charge or encumbrance.  

“Exculpated Claims” has the
meaning assigned to it in Section 10(b).

“Exculpated Parties” has the
meaning assigned to it in Section 10(b).

“Existing Convertible Notes”
means: (i) the series convertible promissory notes issued by the Company on December 14, 2007; (ii) the series convertible promissory notes issued by the
Company on February 9, 2010 and March 1, 2010; and (iii) the Amended and Restated Future Advance Promissory Notes dated as of September 30, 2009 made by the
Company in favor of each of Paramount Biosciences, LLC, The Lindsay A. Rosenwald 2000 Family Trusts Dated December 15, 2000 and Capretti Grandi, LLC.

“Governmental Authority” means
any federal, national, supranational, foreign, state, provincial, local, county, municipal or other government, any governmental, regulatory or administrative
authority, agency, department, bureau, board, commission or official or any quasi-governmental or private body exercising any regulatory, taxing, importing or
other governmental or quasi-governmental authority, or any court, tribunal, judicial or arbitral body, or any Self-Regulatory Organization.  

“Holder” has the meaning
assigned to it in the recitals hereto.  

“Indemnitees” has the meaning
assigned to it in Section 10(a).

“Individual Backstop Cap” has
the meaning assigned to it in the recitals hereto.

“IPO” means an underwritten
initial public offering of the Company’s equity securities (and/or any rights to acquire additional equity securities of the Company).

“Law” means any federal,
national, supranational, foreign, state, provincial, local, county, municipal or similar statute, law, common law, writ, injunction, decree, guideline, policy,
ordinance, regulation, rule, code, Order, constitution, treaty, requirement, judgment or judicial or administrative doctrines enacted, promulgated, issued,
enforced or entered by any Governmental Authority.  

“License Agreement” means that
certain License Agreement, dated as of June 12, 2007, as amended from time to time, between the Company and Dong Wha Pharm. Co. Ltd.

“Losses” has the meaning
assigned to it in Section 10(a).

“Manchester” has the meaning
assigned to it in the preamble hereto.

“Order” means any order, writ,
judgment, injunction, decree, rule, ruling, directive, stipulation, determination or award made, issued or entered by or with any Governmental Authority,
whether preliminary, interlocutory or final.  

3

“PCP Notes” means the 10% Senior Promissory Notes dated January 15, 2009 and June 24, 2009 issued by the Company to Paramount Credit Partners, LLC in the
aggregate principal amount of $2,875,000.

“Person” means any natural
person, partnership, firm, corporation, limited liability company, association, joint venture, trust, Governmental Authority, unincorporated organization or any
other entity.  

“Recapitalization” means the
recapitalization of the Company effected through (i) the Amendment Agreements, providing for (A) the amendment of the Existing Convertible Notes so that upon
the consummation of the Rights Offering all principal and accrued interest outstanding under the Existing Convertible Notes will convert into the right to
receive certain milestone payments based upon the success of the Company and (B) the termination of all existing warrants held by holders of the Existing
Convertible Notes and all other outstanding warrants, options or other securities that are convertible into or exchangeable for equity securities of the Company
(other than the Backstop Warrants, the warrant issued to Timothy Hofer pursuant to his consulting agreement with the Company dated May 26, 2010 and warrants
that will be subject to the reverse stock split in the following clause (ii) and shall consequently have marginal economic value) and (ii) a reverse stock split
and redemption of the Common Stock, or such other reasonable method, so that no more than one share of Common Stock remains outstanding as of the Effective Date
and such share shall be held by Rosenwald.  

“Regulation D” has the meaning
assigned to it in the recitals hereto.

“Rights Offering” has the
meaning assigned to it in the recitals hereto

“Rights Offering Documents”
means (i) the Subscription Forms, (ii) the Subscription Agreements, (iii) the letters from the Company dated March 30, 2011 relating to the Recapitalization and
the Rights Offering, which are attached hereto as Exhibit C, (iv) the Amendment Agreements, (v) the Rights Offering Notes, (vi) the Backstop Warrant for
each Backstop Investor, (vii) this Agreement, (viii) the Security Agreement and (ix) all exhibits, annexes and other attachments to each of the foregoing.

“Rights Offering Notes” means
the Company’s 5% Secured Convertible Promissory Notes in the form attached as Annex A to the Subscription Agreements.

“Rosenwald” has the meaning
assigned to it in the preamble hereto.

“Rosenwald Entities” means
Rosenwald, Paramount Biosciences, LLC, The Lindsay A. Rosenwald 2000 Family Trusts Dated December 15, 2000 and Capretti Grandi, LLC.

“Securities Act” means the
Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder, or any successor statute.  

“Security Agreement” means the
Security Agreement contemplated by Section 4 of the Rights Offering Notes, in form and substance satisfactory to each Backstop Investor.

4

“Self-Regulatory Organization” means any securities exchange, futures exchange, contract market, any other exchange or corporation or similar
self-regulatory body or organization applicable to a party to this Agreement.  

“Subscription Agreements” means
the Subscription Agreements between the Company and the Holders pursuant to which Holders subscribe for and purchase Rights Offering Notes in the Rights
Offering. 

“Subscription Commencement Date” has the meaning assigned to it in Section 2.1(a).

“Subscription Expiration Date”
has the meaning assigned to it in Section 2.1(a).

“Subscription Forms” means the
Subscription Forms pursuant to which Holders subscribe for Rights Offering Notes in the Rights Offering. 

“Subsequent Closing Date” has
the meaning assigned to it in Section 2.1(d).

“Subsequent Closing Notice” has
the meaning assigned to it in Section 2.1(d).

“Subsidiaries” of any Person
means any Person of which (or in which), directly or indirectly, more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to
elect a majority of the board of directors of such corporation (irrespective of whether at the time capital stock of any other class or classes of such
corporation shall or might have voting power upon the occurrence of any contingency), (b) the interest in the capital or profits of such partnership, joint
venture or limited liability company or other Person or (c) the beneficial interest in such trust or estate is at the time owned by such first Person, or by
such first Person and one or more of its other Subsidiaries or by one or more of such Person’s other Subsidiaries.  

Section 2.

RIGHTS OFFERING;
BACKSTOP; BACKSTOP WARRANTS.  

2.1

Rights Offering.

(a)

The Company shall commence the Rights Offering
on or before April 7, 2011 (the “Subscription Commencement Date”) and the Rights Offering shall remain open until no later than 5:00 p.m., New
York City time, on April 22, 2011 (the “Subscription Expiration Date”).  The Rights Offering shall be conducted and consummated on the
terms, subject to the conditions and in accordance with the Rights Offering Documents.  

(b)

Manchester shall subscribe in the Rights
Offering for the maximum aggregate principal amount of Rights Offering Notes that Manchester is entitled to subscribe in the Rights Offering, which amount is
set forth on Exhibit A attached hereto, pursuant to the terms and conditions of a Subscription Agreement.  Rosenwald shall subscribe, and shall
cause each of the Rosenwald Entities to subscribe, in the Rights Offering for the maximum aggregate principal amount of Rights Offering Notes that each such
Rosenwald Entity is entitled to subscribe in the Rights Offering, which amounts are set forth on Exhibit A attached hereto, pursuant to the terms and
conditions of a Subscription Agreement.

5

(c)

The Company shall give to the Backstop Investors
as soon as reasonably practicable, but in no event later than two Business Days, after the Subscription Expiration Date, (i) written notification (the “Effective Date Notice”) setting forth (A) the total principal amount of Rights Offering Notes subscribed for by Holders in the Rights Offering; (B)
each Backstop Investor’s Individual Backstop Cap; (C) the targeted Effective Date; and (D) whether the Company wishes each Backstop Investor to purchase
all or a lesser percentage (provided that such percentage is the same for each Backstop Investor) of the Individual Backstop Cap on the Effective Date and (ii)
a subscription form to be completed by each Backstop Investor to facilitate such Backstop Investor’s subscription for the Rights Offering Notes purchased
pursuant to this Agreement.  The written notification and subscription form described herein shall be substantially in the form included in the Rights
Offering Documents.  

(d)

To the extent that the Company does not require
the Backstop Investors to purchase their respective entire Individual Backstop Cap on the Effective Date, the Company may require the Backstop Investors to
purchase all or a lesser remaining percentage (provided that such percentage is the same for each Backstop Investor) of the Individual Backstop Cap on any
subsequent date (each, a “Subsequent Closing Date”) by giving to the Backstop Investors, at least five Business Days prior to such Subsequent
Closing Date, a written notification (a “Subsequent Closing Notice”) setting forth the percentage (provided that such percentage is the same
for each Backstop Investor) of the Individual Backstop Cap that the Company requires each Backstop Investor to purchase on such Subsequent Closing Date.

(e)

Notwithstanding anything in this Agreement to
the contrary, (a) the minimum principal amount of Rights Offering Notes to be purchased by each Backstop Investor at each Closing shall be not less than
$100,000 and (b) the maximum number of Subsequent Closing Dates upon which the Backstop Investors shall be required to purchase Backstop Notes hereunder shall
not exceed three.

2.2

Backstop.  

(a)

On the terms and subject to the conditions
contained herein, and in reliance on the representations and warranties set forth in this Agreement, each of the Backstop Investors hereby agrees, severally and
not jointly, to purchase on the Effective Date or a Subsequent Closing Date (as applicable and as set forth in the Effective Date Notice and/or a Subsequent
Closing Notice), and the Company hereby agrees to sell and issue to each such Backstop Investor, the principal amount of Rights Offering Notes as set forth in
the Effective Date Notice or such Subsequent Closing Notice, as applicable, provided that in no event shall a Backstop Investor be required to purchase
hereunder an amount of Rights Offering Notes in excess of either (i) its Individual Backstop Cap or (ii) the percentage of the Individual Backstop Cap of the
other Backstop Investor that represents the amount of Rights Offering Notes actually purchased by such other Backstop Investor at such time.  The Rights
Offering Notes that each of the Backstop Investors is required to purchase pursuant to this Section 2.2(a) are referred to herein as such Backstop
Investor’s “Backstop Notes.” 

(b)

Each closing of the purchase and sale of
Backstop Notes hereunder, whether on the Effective Date or a Subsequent Closing Date (each, a “Closing Date”), shall be referred to as a “Closing”.  At each Closing, (i) payment for the Backstop Notes that each

6

Backstop Investor has agreed to
purchase shall be effected by each such Backstop Investor wiring an amount equal to the aggregate principal amount of such Backstop Notes to an account of the
Company identified to each Backstop Investor at least five days prior to such Closing and (ii) the Company shall deliver to each Backstop Investor the Backstop
Notes in the form of grid notes (or adjustments to such grid notes with respect to Subsequent Closing Dates) and such certificates, documents or instruments
required to be delivered by it to such Backstop Investor pursuant to the Rights Offering Documents.    

2.3

Backstop Warrants.  As consideration
for each Backstop Investor’s commitment to purchase Backstop Notes, the Company hereby agrees to issue to each Backstop Investor, on the Effective Date, a
warrant, in the form attached hereto as Exhibit B for the applicable Backstop Investor (a “Backstop Warrant”), to purchase that number
of fully-paid and non-assessable shares (subject to adjustment as provided therein) of Common Stock equal to (i) 50% of the Backstop Commitment Amount divided
by (ii) the price at which shares of Common Stock are sold in an IPO.  The exercise price for such Backstop Warrants shall equal 100% of the price at which
shares of Common Stock are sold in such IPO.   

Section 3.

REPRESENTATIONS AND
WARRANTIES OF THE COMPANY.  The Company hereby represents and warrants to Manchester as of the date hereof, as of the Effective Date and as of each
Subsequent Closing Date (except for representations and warranties that are made as of a specific date, which are made only as of such date) as follows: 

3.1

Organization and Qualification; Subsidiaries.  The Company has been duly organized and is validly existing and is in good standing under the laws of its jurisdiction of organization, with the
requisite power and authority to own its properties and conduct its business as currently conducted.  The Company has no Subsidiaries.

3.2

Authorization; Enforcement; Validity.
 The Company has all necessary corporate power and authority to enter into this Agreement and to carry out its obligations hereunder (including, without
limitation, the issuance of the Backstop Notes and the Backstop Warrants) in accordance with the terms hereof.  The execution and delivery by the Company
of, the performance by the Company of its obligations under, and the consummation of the transactions contemplated by, this Agreement (including, without
limitation, the issuance of the Backstop Notes and the Backstop Warrants), have been duly authorized by all requisite action on the part of the Company, and no
other action on the part of the Company is necessary to authorize the execution and delivery by the Company of, the performance by the Company of its
obligations under, or the consummation of the transactions contemplated by, this Agreement.  This Agreement has been duly executed and delivered by the
Company, and assuming due authorization, execution and delivery by the other parties hereto, this Agreement constitutes the legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium or similar Laws now
or hereafter in effect relating to creditors’ rights generally and subject to general principles of equity.  

3.3

No Conflicts.  The execution and
delivery by the Company of, the performance by the Company of its obligations under, and the consummation of the transactions contemplated by, this Agreement
(including, without limitation, the issuance of the Backstop Notes and the

7

Backstop Warrants) do not and will not:
(i) violate, conflict with or result in the breach of the Company’s certificate of incorporation or bylaws; (ii) conflict with or violate any Law or
Order applicable to the Company or any of its assets or properties; or (iii) violate, conflict with, result in any breach of, constitute a default (or an
event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent (other than those consents that have been
obtained) under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, any Contract (including the
License Agreement) to which the Company is a party or to which any of its assets or properties are subject, or result in the creation of any Encumbrance on any
of its assets or properties.  

3.4

Consents and Approvals.  The
execution and delivery by the Company of, the performance by the Company of its obligations under, and the consummation of the transactions contemplated by,
this Agreement do not require any consent, approval, authorization or other Order of, action by, filing with or notification to, any Governmental Authority or
any other Person under any of the terms, conditions or provisions of any Law or Order applicable to the Company or by which any of its assets or properties may
be bound or any Contract to which the Company is a party or by which the Company or any of its assets or properties may be bound, except for such consents which
have been obtained and such consents, approvals, authorizations, registrations or qualifications as may be reasonably required under state securities or
“blue sky” laws in connection with the issuance of the Backstop Notes.  

3.5

Securities Act.  Assuming the
accuracy of each Backstop Investor’s representations and warranties hereunder, the offerings of the Backstop Notes and the Backstop Warrants are exempt
from the registration requirements of the Securities Act.

3.6

License Agreement.  The License
Agreement is in full force and effect, and the Company is not in default, and has not committed any act or omission that, with the giving of notice or lapse of
time or both, would constitute a default, under the License Agreement.

3.7

Title to Properties and Assets.  The
Company has good and marketable title to its properties and assets, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than
those resulting from taxes which have not yet become delinquent.

3.8

No Litigation.  There is no claim,
action, suit, proceeding, arbitration, complaint, charge, governmental or other proceeding or investigation pending or, to the knowledge of the Company,
threatened against the Company or affecting the properties or assets of the Company or, as to matters related to the Company, against any officer, director or
stockholder or key employee of the Company, in any case, that has had or could have a material affect on the Company.

3.9

Completeness of Disclosure.  No
representation or warranty made by the Company in this Agreement, and no statement made by the Company in any of the Rights Offering Documents or any other
certificate or other document furnished or to be furnished to the Company pursuant hereto or thereto, or in connection with the negotiation, execution,
performance or consummation of this Agreement or the Rights Offering Documents, contains or will contain any untrue statement of material fact or omits or will
omit to state a material fact required to be stated herein or therein or necessary to make any statement herein or therein not

8

misleading.  Except as
specifically set forth in this Agreement or in the Rights Offering Documents, there are no facts or circumstances of which the Company is aware that has had or
could reasonably be expected to have, individually or in the aggregate, a material adverse effect on the condition (financial or otherwise), operations or
results of operations of the Company.

Section 4.

REPRESENTATIONS AND
WARRANTIES OF EACH BACKSTOP INVESTOR.  Each Backstop Investor represents and warrants, severally and not jointly, to the Company as of the date
hereof, as of the Effective Date and as of each Subsequent Closing Date (except for representations and warranties that are made as of a specific date, which
are made only as of such date), as follows: 

4.1

Authorization; Enforcement; Validity.
 To the extent that such Backstop Investor is an entity, such Backstop Investor has all necessary corporate or equivalent power and authority to enter into
this Agreement and to carry out its obligations hereunder in accordance with the terms hereof.  To the extent that such Backstop Investor is an entity,
such execution and delivery by such Backstop Investor of, the performance by such Backstop Investor of its obligations under, and the consummation of the
transactions contemplated by, this Agreement have been duly authorized by all requisite action on the part of the such Backstop Investor, and no other action on
the part of such Backstop Investor is necessary to authorize the execution and delivery by such Backstop Investor of, the performance by such Backstop Investor
of its obligations under, or the consummation of the transactions contemplated by, this Agreement.  This Agreement has been duly executed and delivered by
such Backstop Investor, and assuming due authorization, execution and delivery by the other parties hereto, this Agreement constitutes the legal, valid and
binding obligation of such Backstop Investor, enforceable against such Backstop Investor in accordance with its terms, subject to bankruptcy, insolvency,
reorganization, moratorium or similar Laws now or hereafter in effect relating to creditors’ rights generally and subject to general principles of equity.
 

4.2

No Conflicts.  The execution and
delivery by such Backstop Investor of, the performance by such Backstop Investor of its obligations under, and the consummation of the transactions contemplated
by, this Agreement do not and will not (i) violate any provision of the organizational documents of such Backstop Investor or (ii) conflict with or violate any
Law or Order applicable to such Backstop Investor or any of its assets or properties.  

4.3

Consents and Approvals.  No consent,
approval, order, authorization, registration or qualification of or with any court or Governmental Authority or body having jurisdiction over such Backstop
Investor is required in connection with the execution and delivery of, the performance under, or the consummation of the transactions contemplated by, this
Agreement.  

4.4

Accredited Investor Status.  Such
Backstop Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act.  

Section 5.

REPRESENTATIONS AND
WARRANTIES OF THE COMPANY AND ROSENWALD. Each of the Company and Rosenwald represents and warrants, severally and not jointly, to Manchester as of
the date hereof, as of the Effective Date and as of each Subsequent Closing Date (except for representations and warranties that are made as of a specific date,
which are made only as of such date), as follows

9

5.1

Approval of Amendment Agreements.
 Other than the consents of Manchester and Rosenwald, each Amendment Agreement has been duly approved by the requisite holders thereof, and no further
consent or approval is needed from any other Person in order for such Amendment Agreement to be effective. 

Section 6.

ADDITIONAL COVENANTS.  

6.1

Further Assurances.  Each party
hereto shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements,
certificates, instruments and documents, as any other party hereto may reasonably request in order to carry out the intent and accomplish the purposes of this
Agreement and the consummation of the transactions contemplated hereby.  

6.2

Taxes.  The Company will pay, and
save and hold each Backstop Investor harmless from, any and all liabilities (including interest and penalties) with respect to, including resulting from any
delay or failure in paying, all stamp and other taxes (other than income taxes), if any, which may be payable or determined to be payable on the execution and
delivery or acquisition of the Backstop Notes and/or Backstop Warrants hereunder.

6.3

Consent Rights.  The Company shall
obtain each Backstop Investor’s written consent prior to taking any material action prior to, or through the completion of, the IPO, including, without
limitation, amending the License Agreement and establishing the terms of the IPO.

6.4

Board Member.  Manchester shall have
the right to appoint one member to the Company’s board of directors.  

6.5

Access to Information. The Company shall
permit, during normal business hours, each Backstop Investor, or any employees, agents or representatives thereof, to examine the Company’s records and
books of account, including, without limitation, stockholder and investor (including Holders of the Rights Offering Notes) lists, and to visit and inspect the
properties, assets, operations and business of the Company, and to discuss the affairs, finances and accounts of the Company with members of the Company’s
senior management.  In connection with the foregoing, the Company shall provide copies of all such records and books of account to a Backstop Investor
promptly following such Backstop Investor’s request therefor.

6.6

Negative Covenants.  The
Company shall not incur additional indebtedness that ranks in priority pari passu or senior to the Rights Offering Notes without obtaining the consent of the
Backstop Investors.  The Company shall not create, incur, assume or suffer to exist any lien upon or with respect to any of its property or assets, whether
now owned or after acquired, except in connection with the Rights Offering Notes.  The Company shall not convey, sell, lease, transfer or otherwise dispose
of, in one or more transactions, all or any part of its business, property or assets, whether now owned or hereafter acquired.  Except for the Backstop
Warrants and securities issued in connection with the IPO, the Company shall not issue any equity securities, or any debt
securities that are convertible into or exchangeable for equity securities, without obtaining the consent of the Backstop Investors.

10

6.7

PCP Notes.  Rosenwald hereby agrees
to make all interest payments to the other holders of the PCP Notes on behalf of the Company until the consummation of the IPO.

6.8

Voting of Rights Offering Notes.
 Manchester shall have the right to direct all votes, consents, forbearances and/or other approvals with respect to all Rights Offering Notes held by the
Backstop Investors and the Rosenwald Entities and all Rights Offering Notes that were originally subscribed for by the Backstop Investors and the Rosenwald
Entities.  

6.9

Use of Proceeds.  The Company shall
use the proceeds from the offering of the Rights Offering Notes in accordance with Section 7.4.7 of Amendment No. 3 to the License Agreement.

Section 7.

CONDITIONS TO THE
BACKSTOP INVESTORS’ OBLIGATIONS.  The obligations of each Backstop Investor to (a) subscribe for and purchase the Rights Offering Notes
pursuant to Section 2.1(b) hereof and (b) to purchase the Backstop Notes pursuant to this Agreement on each Closing Date shall be subject to the
satisfaction at or prior to such Closing Date of each of the following conditions, any one or more of which may be waived in writing by mutual consent of the
Backstop Investors: 

7.1

Representations, Warranties and Covenants.  (a) All of the representations and warranties made by the Company in this Agreement that are qualified by materiality or material adverse effect
shall be true and correct in all respects as of the date hereof and as of such Closing Date as though made at and as of such Closing Date (except to the extent
such representations and warranties expressly speak as of an earlier date, which shall be true and correct in all respects as of such date) and all of the
representations and warranties made by the Company in this Agreement that are not qualified by materiality or material adverse effect shall be true and correct
in all material respects as of the date hereof and as of such Closing Date as though made at and as of such Closing Date (except to the extent such
representations and warranties expressly speak as of an earlier date, which shall be true and correct in all material respects as of such date); (b) the Company
shall have performed and complied in all respects with all agreements and covenants required by this Agreement to be performed by the Company on or prior to
such Closing Date; and (c) at such Closing there shall be delivered to each Backstop Investor a certificate signed by a duly authorized representative of the
Company to the effect that all closing conditions under this Section 7 have been satisfied

7.2

No Orders or Actions or Laws.  No
temporary restraining order, preliminary or permanent injunction or other Order, and no Action, shall be in effect or have been instituted or threatened
enjoining, prohibiting or otherwise preventing, or seeking to enjoin, prohibit or otherwise prevent, the consummation of the transactions contemplated by this
Agreement.  No Law shall have been enacted or shall be deemed applicable to the transactions contemplated by this Agreement that makes the consummation of
such transactions illegal.

7.3

Recapitalization.  The
Recapitalization shall have been successfully consummated, and all necessary approvals and consents required from the Company’s security holders and any
other Person shall have been obtained prior to such consummation.

11

7.4

License Agreement.  The License
Agreement shall be in full force and effect, and the Company shall not be in default, or have committed any act or omission that, with the giving of notice or
lapse of time or both, would constitute a default, under the License Agreement.  No temporary restraining order, preliminary or permanent injunction or
other Order, and no Action, shall be in effect or have been instituted or threatened enjoining, prohibiting or otherwise preventing, or seeking to enjoin,
prohibit or otherwise prevent, the consummation of the transactions contemplated by the License Agreement.  No Law shall have been enacted or shall be
deemed applicable to the transactions contemplated by the License Agreement that makes the consummation of such transactions illegal.

7.5

Backstop Warrant.  Each Backstop
Warrant shall have been issued.  With respect to each Subsequent Closing Date, each Backstop Warrant shall be in full force and effect, and the Company
shall not be in default, or have committed any act or omission that, with the giving of notice or lapse of time or both, would constitute a default, under such
Backstop Warrant.  

7.6

Other Backstop Investor.  The other
Backstop Investor shall have satisfied in full its payment obligations in connection with such Closing and all prior Closings.

7.7

Rights Offering.  The Rights
Offering shall have been conducted in accordance with the terms and conditions of the Rights Offering Documents.

7.8

Security Agreement.  The Security
Agreement shall have been executed and delivered and be in full force and effect, and all security documents contemplated thereby and such other documents,
instruments and/or agreements that a Backstop Investor may request to perfect its security interest in the collateral described in Section 4 of the Rights
Offering Notes in all relevant jurisdictions, including, to the extent applicable, landlord consents, account control agreements and any filings necessary to
perfect the Holders’ security interest in the Company’s intellectual property, shall have been executed and delivered and/or made, as applicable, and
be in full force and effect.

7.9

Dong Wha Acknowledgment.  The
Backstop Investors shall have received an acknowledgement from Dong Wha Pharm. Co. Ltd. that Section 7.4.7 of Amendment No. 3 to the License Agreement has been
satisfied.  

Section 8.

CONDITIONS TO THE
COMPANY’S OBLIGATIONS.  The obligations of Company to issue and sell the Backstop Notes to each Backstop Investor pursuant to this Agreement
on each Closing Date shall be subject to the satisfaction at or prior to such Closing Date of each of the following conditions, any one or more of which may be
waived in writing by the Company: 

8.1

Representations and Warranties.  (a)
All of the representations and warranties made by such Backstop Investor in this Agreement that are qualified by materiality or material adverse effect shall be
true and correct in all respects as of the date hereof and as of such Closing Date as though made at and as of such Closing Date (except to the extent such
representations and warranties expressly speak as of an earlier date, which shall be true and correct in all respects as of such date) and all of the
representations and warranties made by such Backstop Investor in this Agreement that are not qualified by materiality or material adverse effect shall be

12

true and correct in all material
respects as of the date hereof and as of such Closing Date as though made at and as of such Closing Date (except to the extent such representations and
warranties expressly speak as of an earlier date, which shall be true and correct in all material respects as of such date) and (b) such Backstop Investor shall
have performed and complied in all material respects with all agreements and covenants required by this Agreement to be performed by such Backstop Investor on
or prior to such Closing Date.  

8.2

No Orders or Actions or Laws.  No
temporary restraining order, preliminary or permanent injunction or other Order, and no Action, shall be in effect or have been instituted or threatened
enjoining, prohibiting or otherwise preventing, or seeking to enjoin, prohibit or otherwise prevent, the consummation of the transactions contemplated by this
Agreement.  No Law shall have been enacted or shall be deemed applicable to the transactions contemplated by this Agreement that makes the consummation of
such transactions illegal.  

8.3

Recapitalization.  The
Recapitalization shall have been successfully consummated, and all necessary approvals and consents required from the Company’s security holders and any
other Person shall have been obtained prior to such consummation.

Section 9.

TERMINATION.
 

9.1

Mutual Termination.  This Agreement
may be terminated by the mutual written consent of the Company and each of the Backstop Investors.  

9.2

Termination by the Backstop Investors.
 This Agreement may be terminated at any time by either of the Backstop Investors (a) upon the failure of any of the conditions set forth in Section 7
hereof to be satisfied on or prior to the Effective Date or at any time thereafter; (b) upon the termination of the License Agreement; or (c) at any time on or
after June 30, 2011 if all the Backstop Notes have not been purchased by the Backstop Investors by such date.  

9.3

Effect of Termination.  If this
Agreement is terminated pursuant to this Section 9, the obligations of such parties contained in Sections 2.3, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 10, 11.2
through 11.15 and this Section 9 shall survive any such termination.    

Section 10.

INDEMNIFICATION;
EXCULPATION. 

(a)

Indemnification.  The Company will
indemnify, save and hold harmless Manchester, and each of its Affiliates and its and their respective directors, officers, stockholders, employees, partners,
members, managers, representatives, attorneys, other professional advisors and agents and all of their respective heirs, successors, legal administrators and
permitted assigns (collectively, the “Indemnitees”) from and against all losses, claims, damages, liabilities, costs and expenses (including,
without limitation, the costs and expenses of investigation and reasonable attorneys’ fees and the costs and expenses of enforcing this indemnity,
including reasonable attorneys’ fees), as incurred by any or all of the Indemnitees in connection with any claim against them by a third party in
connection with or arising from the execution, delivery, performance and consummation of this Agreement or the Rights Offering (collectively, the “Losses”); provided, however, that the foregoing indemnity will not apply to Losses of an Indemnitee to the extent that they are found
by a final, non-appealable judgment of a court of competent jurisdiction to have resulted from such Indemnitee’s bad faith, willful

13

misconduct or gross negligence.
 This Section 10(a) will be in addition to the rights of each and all of the Indemnitees to bring an action against the Company for breach of any term of
this Agreement.  The Company acknowledges and agrees that each and all of the Indemnitees shall be treated as third-party beneficiaries with rights to
bring an action against the Company under this Section 10(a).

(b)

Exculpation.  To the fullest extent
permitted by applicable Law, the Company shall not assert, and the Company hereby waives, any claim against the Backstop Investors and each of their Affiliates
and their respective directors, officers, stockholders, employees, partners, members, managers, representatives, attorneys, other professional advisors and
agents and all of their respective heirs, successors, legal administrators and permitted assigns (collectively, the “Exculpated Parties”), on
any theory of liability, for special, indirect, consequential or punitive damages, as opposed to direct or actual damages, (whether or not the claim therefor is
based on contract, tort or duty imposed by any applicable legal requirement) to the extent any such claim arises out of, is in connection with, is a result of,
or is in any way related to, this Agreement or the Rights Offering, and the Company hereby waives, releases and agrees not to sue upon any such claim or any
such damages, whether or not accrued and whether or not known or suspected to exist in its favor (collectively, the “Exculpated Claims”);
provided, however, that the foregoing exculpation will not apply to damages to the extent that they are found by a final, non-appealable judgment
of a court of competent jurisdiction to have resulted from such Exculpated Party’s bad faith, willful misconduct or gross negligence.  

Section 11.

MISCELLANEOUS.
 

11.1

Survival.  The representations and
warranties made in this Agreement will survive the execution and delivery of this Agreement and each Closing for the length of the applicable statute of
limitations with respect thereto.  

11.2

No Waiver of Rights.  All waivers
hereunder must be made in writing, and the failure of any party at any time to require another party’s performance of any obligation under this Agreement
shall not affect the right subsequently to require performance of that obligation.  Any waiver of any breach of any provision of this Agreement shall not
be construed as a waiver of any continuing or succeeding breach of such provision or a waiver or modification of any other provision.  

11.3

Notices.  All notices, requests,
claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon
receipt) by delivery in person, by an internationally recognized overnight courier service, by facsimile or registered or certified mail (postage prepaid,
return receipt requested) to the respective parties hereto at the following addresses (or at such other address for any party as shall be specified by such
party in a notice given in accordance with this Section 11.3) 

(a)

If to the Company, to:  

IASO Pharma Inc.

12707 High Bluff Drive

14

Suite 200

San Diego, California 92130 

Attention: Matthew A. Wikler, M.D.

Telephone: (858) 350-4312

Facsimile: (858) 332-1702

with a copy (which shall not constitute notice to the
Company) to 

Olshan Grundman Frome Rosenzweig & Wolosky LLP

Park Avenue Tower

65 East 55th Street

New York, New York 10022

Attention: Yehuda Markovits

Telephone: (212) 451-2300

Facsimile: (212) 451-2222

(b)

If to Manchester, to:

Manchester Securities Corp.

c/o Elliott Management Corporation

712 Fifth Avenue, 35th Floor

New York, NY 10019

Attention: David Bernfeld and Elliot Greenberg

Telephone: (212) 974-6000

Facsimile: (212) 478-2811

with a copy (which shall not constitute notice to
Manchester) to 

Kleinberg, Kaplan, Wolff & Cohen, P.C.

551 Fifth Avenue, 18th Floor

New York, NY 10176

Attention: Max Karpel

Telephone: (212) 986-6000

Facsimile: (212) 986-8866

(c)

If to Rosenwald, to:

Lindsay A. Rosenwald, M.D.

787 Seventh Avenue

48th Floor

New York, NY 10019

Attention: Lindsay A. Rosenwald, M.D.

Telephone: (212) 554-4366

Facsimile: (212) 554-4488

11.4

Headings.  The section and
subsection headings in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.  

15

11.5

Construction.  The parties hereto
and their respective legal counsel participated in the preparation of this Agreement and, therefore, this Agreement shall be construed neither against nor in
favor of any of the parties hereto, but rather in accordance with the fair meaning thereof.  

11.6

Severability.  If any term or other
provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement
shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party hereto.  Upon such determination that any term or other provision is invalid, illegal or incapable of being
enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in
an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.  

11.7

Entire Agreement.  This Agreement
(including the Exhibits hereto) and the agreements and documents referenced herein constitute the entire agreement of the parties hereto with respect to the
subject matter hereof and supersede all prior agreements and undertakings, both written and oral, among the parties hereto with respect to the subject matter
hereof.  

11.8

Successors and Assigns.  This
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.  Neither this
Agreement nor any of the rights, interests or obligations under this Agreement will be assigned by any party (whether by operation of law or otherwise) without
the prior written consent of the other parties, provided that each Backstop Investor shall be entitled to assign this Agreement to its Affiliates upon
prior written notice to the Company.

11.9

No Third Party Beneficiaries.  This
Agreement shall be binding upon and inure solely to the benefit of the parties hereto and their respective successors and permitted assigns and, except as
expressly set forth in Section 10, nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right,
benefit or remedy of any nature whatsoever under or by reason of this Agreement.  

11.10

Amendment.  This Agreement may not
be altered, amended or modified except by a written instrument executed by or on behalf of the Company and the Backstop Investors.    

11.11

Governing Law.  This Agreement shall
be interpreted, construed and enforced in accordance with the laws of the State of New York, without regard to the conflicts of law principles thereof.  

11.12

Consent to Jurisdiction.  Each of
the parties hereto (a) irrevocably and unconditionally agrees that any actions, suits or proceedings, at Law or equity, arising out of or relating to this
Agreement or any agreements or transactions contemplated hereby shall be heard and determined exclusivity in the state and federal courts located in New York
County, New York; (b) irrevocably submits to the jurisdiction of such courts in any such action, suit or proceeding; (c) consents that any such action, suit or
proceeding may be brought in such courts and waives any objection that such party may now or hereafter have to the venue or jurisdiction

16

or that such action or proceeding
was brought in an inconvenient court; and (d) agrees that service of process in any such action, suit or proceeding may be effected by providing a copy thereof
by any of the methods of delivery permitted by Section 11.3 to such party at its address as provided in Section 11.3 (provided that nothing herein shall affect
the right to effect service of process in any other manner permitted by Law).  

11.13

Waiver of Jury Trial.  EACH OF THE
PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY
OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.  EACH OF THE PARTIES HERETO HEREBY (A)
CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS, AS APPLICABLE,
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 11.13.  

11.14

Counterparts.  This Agreement may be
executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of
which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.  

11.15

Rules of Construction.  Unless the
context of this Agreement clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the term
“including” is not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase
“and/or.” The words “hereof,” “herein,” “hereby,” “hereunder” and similar terms in this Agreement refer to
this Agreement as a whole and not to any particular provision of this Agreement.  Section, subsection, clause, schedule, annex and exhibit references are
to this Agreement unless otherwise specified.  Any reference to this Agreement shall include all alterations, amendments, changes, extensions,
modifications, renewals, replacements, substitutions and supplements thereto and thereof, as applicable.  Whenever the context may require, any pronoun
includes the corresponding masculine, feminine and neuter forms.  

[Signature Page Follows]

17

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the date first written above.  

				

	 
	IASO PHARMA INC.

	 
	 

	 
	 

	 
	By:

	/s/
Matthew A. Wikler

	 
	 
	
Name:

	Matthew A. Wikler, M.D.

	 
	 
	
Title:

	President and CEO

				

	 
	MANCHESTER
SECURITIES CORP.

	 
	 

	 
	 

	 
	By:

	/s/
Elliot Greenberg

	 
	 
	
Name:

	Elliot Greenberg

	 
	 
	
Title:

	Vice President

		
	 
	 

	 
	 

	 
	
/s/ Lindsay A. Rosenwald

	 
	LINDSAY A. ROSENWALD, M.D.

Signature Page to Backstop Commitment Agreement

Exhibit A

Backstop Investors; Rights Offering Notes

			
	
Backstop Investor

	
Aggregate Principal Amount of Existing Convertible Notes

	
Aggregate Principal Amount of Rights Offering Notes

	Rosenwald Entites

	 
	 

	Lindsay A. Rosenwald, M.D.

	$500,000

	$140,500

	Paramount BioSciences, LLC

	$2,326,350

	$653,704

	The Lindsay A. Rosenwald 2000 Family Trusts Dated
December 15, 2000

	$660,000

	$185,460

	Capretti Grandi, LLC

	$50,000

	$14,050

	Total Rosenwald Entities:

	$3,536,350

	$993,714

	 
	 
	 

	Manchester Securities Corp.

	$2,000,000

	$562,000

	 
	 
	 

	Total Backstop Investors:

	$5,536,350

	$1,555,714

Exhibit B

Forms of Backstop Warrant

Exhibit C

Letter Agreements

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]